Amalgamated Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.04M Buy
88,001
+1,672
+2% +$91.6K 0.03% 437
2026
Q1
$4.88M Buy
86,329
+949
+1% +$55.3K 0.04% 436
2025
Q4
$5.07M Sell
85,380
-2,187
-2% -$119K 0.04% 407
2025
Q3
$4.74M Buy
87,567
+98
+0.1% +$5.61K 0.03% 439
2025
Q2
$4.81M Buy
87,469
+149
+0.2% +$8.77K 0.04% 412
2025
Q1
$6.17M Sell
87,320
-3,728
-4% -$251K 0.05% 295
2024
Q4
$5.99M Buy
91,048
+382
+0.4% +$25.6K 0.05% 320
2024
Q3
$6.37M Sell
90,666
-5,256
-5% -$439K 0.05% 308
2024
Q2
$7.9M Buy
95,922
+85,177
+793% +$7.09M 0.07% 233
2024
Q1
$938K Sell
10,745
-5,619
-34% -$503K 0.01% 1068
2023
Q4
$1.58M Sell
16,364
-4,303
-21% -$381K 0.01% 992
2023
Q3
$1.83M Buy
20,667
+2,439
+13% +$217K 0.02% 907
2023
Q2
$1.58M Sell
18,228
-302
-2% -$28.4K 0.01% 969
2023
Q1
$1.8M Buy
18,530
+91
+0.5% +$9.43K 0.02% 905
2022
Q4
$1.91M Buy
18,439
+123
+0.7% +$11.5K 0.02% 915
2022
Q3
$1.55M Sell
18,316
-1,197
-6% -$107K 0.02% 945
2022
Q2
$1.62M Buy
19,513
+1,497
+8% +$119K 0.02% 943
2022
Q1
$1.39M Sell
18,016
-1,097
-6% -$91.8K 0.01% 1075
2021
Q4
$1.69M Sell
19,113
-191
-1% -$15.8K 0.01% 1018
2021
Q3
$1.49M Sell
19,304
-1,751
-8% -$138K 0.01% 1063
2021
Q2
$1.76M Buy
21,055
+12,244
+139% +$971K 0.01% 1023
2021
Q1
$665K Sell
8,811
-476
-5% -$38.9K 0.02% 817
2020
Q4
$814K Sell
9,287
-136
-1% -$10.8K 0.03% 679
2020
Q3
$717K Sell
9,423
-153
-2% -$15.5K 0.03% 639
2020
Q2
$1.18M Sell
9,576
-17,977
-65% -$1.79M 0.05% 351
2020
Q1
$2.33M Sell
27,553
-964
-3% -$83.1K 0.06% 310
2019
Q4
$2.41M Buy
28,517
+1,338
+5% +$101K 0.04% 408
2019
Q3
$1.83M Buy
27,179
+5,868
+28% +$452K 0.04% 475
2019
Q2
$1.82M Sell
21,311
-2,837
-12% -$243K 0.04% 451
2019
Q1
$2.15M Buy
24,148
+712
+3% +$66K 0.05% 355
2018
Q4
$2M Sell
23,436
-754
-3% -$71.7K 0.06% 317
2018
Q3
$2.35M Sell
24,190
-569
-2% -$56.8K 0.06% 313
2018
Q2
$2.33M Buy
24,759
+1,954
+9% +$171K 0.06% 315
2018
Q1
$1.85M Buy
22,805
+2,509
+12% +$215K 0.05% 412
2017
Q4
$1.81M Buy
20,296
+2,052
+11% +$178K 0.05% 402
2017
Q3
$1.7M Buy
18,244
+402
+2% +$35.5K 0.05% 362
2017
Q2
$1.62M Buy
17,842
+7,628
+75% +$694K 0.05% 373
2017
Q1
$897K Sell
10,214
-5,445
-35% -$484K 0.04% 491
2016
Q4
$1.3M Buy
15,659
+3,399
+28% +$292K 0.06% 354
2016
Q3
$1.13M Buy
12,260
+456
+4% +$42.9K 0.07% 307
2016
Q2
$1.09M Buy
11,804
+6,500
+123% +$553K 0.06% 323
2016
Q1
$437K Buy
5,304
+1,521
+40% +$124K 0.04% 608
2015
Q4
$396K Sell
3,783
-1,226
-24% -$128K 0.05% 580
2015
Q3
$528K Buy
5,009
+125
+3% +$16.7K 0.06% 470
2015
Q2
$668K Buy
4,884
+375
+8% +$46.5K 0.07% 378
2015
Q1
$562K Buy
4,509
+866
+24% +$91.8K 0.07% 361
2014
Q4
$329K Buy
3,643
+141
+4% +$11.7K 0.05% 531
2014
Q3
$253K Buy
3,502
+276
+9% +$18.1K 0.04% 675
2014
Q2
$201K Sell
3,226
-64
-2% -$3.87K 0.03% 819
2014
Q1
$224K Sell
3,290
-71
-2% -$5.23K 0.04% 701
2013
Q4
$236K Buy
+3,361
New +$228K 0.04% 682

Other funds holding BMRN

Amalgamated Bank's BMRN Position: Q2 2026 in Review

Amalgamated Bank increased its BioMarin Pharmaceuticals (BMRN) stake by 1.9% in Q2 2026, buying an estimated $91.6K and bringing the position to 88,001 shares worth $5.04M. The position accounts for 0.03% of the portfolio, ranked #437.

Amalgamated Bank first reported a position in BMRN in Q4 2013 and has held it in 51 quarters since. The position peaked at $7.9M in Q2 2024. 257 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Amalgamated Bank held 88,001 shares of BioMarin Pharmaceuticals worth $5.04M as of Q2 2026.
  • Amalgamated Bank bought 1,672 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $91.6K.
  • BioMarin Pharmaceuticals made up 0.03% of Amalgamated Bank's portfolio in Q2 2026, its #437 holding.
  • Amalgamated Bank first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 51 quarters since.
  • Amalgamated Bank's BioMarin Pharmaceuticals position peaked at $7.9M in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.